Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment

Inclusion criteria

• Diagnosis in one or both eyes of bacterial conjunctivitis based on:

• symptoms less than or equal to 24 hours prior to first visit
• rating > or equal to 1 for bulbar conjunctival injection
• must have a rating > 1 for conjunctival discharge / exudate in at least one eye (the same eye as bulbar conjunctival injection ) at Visit 1, and
• Must experience some matting in the affected eye(s).
• 1 year of age or older, of any race and either sex
• Able to understand and sign an informed consent that has been approved by an Institutional Review Board; or if the subject is a minor, the informed consent must be signed and understood by the subjects legally authorized representative (parent or guardian). Assent to participate should be obtained from subjects 6 years of age or older unless not allowed by local regulation.
• Must agree to comply with study visit schedule, photographs and other study requirements. If subject is a minor, the parent or guardian must agree to ensure compliance.

Exclusion criteria

• Cannot have had bacterial conjunctivitis as reported by subject (or parent if subject is a minor) for > 24 hours.
• Any current lid disease on clinical examination.
• Known or suspected allergy or hypersensitivity to fluoroquinolones.
• Suspected fungal, viral (e.g. Herpes simplex) or Acanthamoeba infection, based on clinical observation.
• Any systemic or ocular disease or disorder, complicating factors or structural abnormality that would negatively affect the conduct or outcome of the study (e.g., hepatitis, acute or chronic renal insufficiency).
• Use of topical ocular medications during the study period.
• Antibiotics (systemic or topical) may not be used within 7 day of visit 1 or anytime after this visit for the duration of the study.
• Women of childbearing potential not using reliable means of birth control.
• Women who are pregnant or lactating.
• Enrollment of more than one person per household at the same time.
• Enrollment of the investigator or his or her staff, family members of the investigator, family members of the investigator's staff, or individuals living in the households of these individuals.
• Participation in any investigational drug or device study within 30 days of entering this study.